Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.

Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T

Lancet (London, England)26 Jun 2023Cited by 309 (Europe PMC)

PMID37385280DOI10.1016/s0140-6736(23)01053-xPepBankPUB-37385280

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study31

30 results from studies that gave the peptide. 30 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, dulaglutide reduced HbA1c from baseline at 24 weeks.
In plain wordsIn adults with diabetes, dulaglutide reduced blood sugar from baseline at 24 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change at 24 weeks
Study
n = 46
Comparator
Baseline
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1·5 mg · injection · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−1.41%
Dulaglutide at 24 weeks
Source sentences
Summary
versus -0·01% (0·21; -0·12 mmol/mol [2·27]) for the placebo group and -1·41% (0·12; -15·40 mmol/mol [1·29]) for the 1·5 mg dulaglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was change in HbA_1c from baseline to 24 weeks, and secondary endpoints included change in HbA_1c and bodyweight at 36 weeks.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528023
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c changed by -0.43% from baseline at 24 weeks with retatrutide 0.5 mg.
In plain wordsIn adults with type 2 diabetes, HbA1c fell from baseline at 24 weeks with retatrutide 0.5 mg.
Peptide
Retatrutide
Outcome
DecreaseHbA1c change at 24 weeks, 0.5 mg
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg once weekly · injection · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−0.43%
0.5 mg, week 24
Source sentences
Summary
-0·43% (SE 0·20; -4·68 mmol/mol [2·15]) for the 0·5 mg group
3 context sentences(design, population, supporting numbers)
Summary · context
At 24 weeks, least-squares mean changes from baseline in HbA_1c with retatrutide were
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528001
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c fell by 1.39% from baseline at 24 weeks with retatrutide 4 mg (escalation group).
In plain wordsIn adults with type 2 diabetes, HbA1c fell from baseline at 24 weeks with retatrutide 4 mg.
Peptide
Retatrutide
Outcome
DecreaseHbA1c change at 24 weeks, 4 mg escalation
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4 mg once weekly (escalation group) · injection · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−1.39%
4 mg escalation, week 24
Source sentences
Summary
-1·39% (0·14; -15·24 mmol/mol [1·56]) for the 4 mg escalation group
3 context sentences(design, population, supporting numbers)
Summary · context
At 24 weeks, least-squares mean changes from baseline in HbA_1c with retatrutide were
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528002
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c fell by 1.30% from baseline at 24 weeks with retatrutide 4 mg.
In plain wordsIn adults with type 2 diabetes, HbA1c fell from baseline at 24 weeks with retatrutide 4 mg.
Peptide
Retatrutide
Outcome
DecreaseHbA1c change at 24 weeks, 4 mg
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4 mg once weekly · injection · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−1.3%
4 mg, week 24
Source sentences
Summary
-1·30% (0·22; -14·20 mmol/mol [2·44]) for the 4 mg group
3 context sentences(design, population, supporting numbers)
Summary · context
At 24 weeks, least-squares mean changes from baseline in HbA_1c with retatrutide were
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528003
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c fell by 1.99% from baseline at 24 weeks with retatrutide 8 mg (slow escalation).
In plain wordsIn adults with type 2 diabetes, HbA1c fell from baseline at 24 weeks with retatrutide 8 mg.
Peptide
Retatrutide
Outcome
DecreaseHbA1c change at 24 weeks, 8 mg slow escalation
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
8 mg once weekly (slow escalation group) · injection · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−1.99%
8 mg slow escalation, week 24
Source sentences
Summary
-1·99% (0·15; -21·78 mmol/mol [1·60]) for the 8 mg slow escalation group
3 context sentences(design, population, supporting numbers)
Summary · context
At 24 weeks, least-squares mean changes from baseline in HbA_1c with retatrutide were
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528004
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c fell by 1.88% from baseline at 24 weeks with retatrutide 8 mg (fast escalation).
In plain wordsIn adults with type 2 diabetes, HbA1c fell from baseline at 24 weeks with retatrutide 8 mg.
Peptide
Retatrutide
Outcome
DecreaseHbA1c change at 24 weeks, 8 mg fast escalation
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
8 mg once weekly (fast escalation group) · injection · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−1.88%
8 mg fast escalation, week 24
Source sentences
Summary
-1·88% (0·21; -20·52 mmol/mol [2·34]) for the 8 mg fast escalation group
3 context sentences(design, population, supporting numbers)
Summary · context
At 24 weeks, least-squares mean changes from baseline in HbA_1c with retatrutide were
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528005
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c fell by 2.02% from baseline at 24 weeks with retatrutide 12 mg (escalation).
In plain wordsIn adults with type 2 diabetes, HbA1c fell from baseline at 24 weeks with retatrutide 12 mg.
Peptide
Retatrutide
Outcome
DecreaseHbA1c change at 24 weeks, 12 mg escalation
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
12 mg once weekly (escalation group) · injection · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−2.02%
12 mg escalation, week 24
Source sentences
Summary
-2·02% (0·11; -22·07 mmol/mol [1·21]) for the 12 mg escalation group
3 context sentences(design, population, supporting numbers)
Summary · context
At 24 weeks, least-squares mean changes from baseline in HbA_1c with retatrutide were
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528006
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c reductions with retatrutide were significantly greater than with placebo in all groups except 0.5 mg (p<0.0001).
In plain wordsIn adults with type 2 diabetes, retatrutide lowered HbA1c more than placebo in all dose groups except the lowest, 0.5 mg.
Peptide
Retatrutide
Outcome
DecreaseHbA1c vs placebo at 24 weeks, 4 mg and higher
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4, 8 and 12 mg groups · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
reductions with retatrutide were significantly greater (p<0·0001) than placebo in all but the 0·5 mg group
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528007
09HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the HbA1c reduction with retatrutide 0.5 mg was not significantly greater than with placebo.
In plain wordsIn adults with type 2 diabetes, retatrutide 0.5 mg did not lower HbA1c significantly more than placebo.
Peptide
Retatrutide
Outcome
No significant changeHbA1c vs placebo at 24 weeks, 0.5 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg once weekly · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
reductions with retatrutide were significantly greater (p<0·0001) than placebo in all but the 0·5 mg group
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528008
10HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c reduction with retatrutide 8 mg (slow escalation) was greater than with dulaglutide 1.5 mg (p=0.0019).
In plain wordsIn adults with type 2 diabetes, retatrutide 8 mg (slow escalation) lowered HbA1c more than dulaglutide 1.5 mg.
Peptide
Retatrutide
Outcome
DecreaseHbA1c vs dulaglutide at 24 weeks, 8 mg slow escalation
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
8 mg once weekly (slow escalation group) · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
greater than 1·5 mg dulaglutide in the 8 mg slow escalation group (p=0·0019) and 12 mg escalation group (p=0·0002)
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528009
11HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c reduction with retatrutide 12 mg (escalation) was greater than with dulaglutide 1.5 mg (p=0.0002).
In plain wordsIn adults with type 2 diabetes, retatrutide 12 mg lowered HbA1c more than dulaglutide 1.5 mg.
Peptide
Retatrutide
Outcome
DecreaseHbA1c vs dulaglutide at 24 weeks, 12 mg escalation
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
12 mg once weekly (escalation group) · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
greater than 1·5 mg dulaglutide in the 8 mg slow escalation group (p=0·0019) and 12 mg escalation group (p=0·0002)
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528010
12HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the reported HbA1c comparisons involving dulaglutide were consistent at 36 weeks.
In plain wordsIn adults with diabetes, the HbA1c findings involving dulaglutide were consistent at 36 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedConsistency of HbA1c findings at 36 weeks
Study
n = 71
Comparator
Retatrutide dose groups
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1·5 mg · injection · 36 weeksAs given in this study (human).
Source sentences
Summary
Findings were consistent at 36 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
HbA_1c reductions with retatrutide were significantly greater (p<0·0001) than placebo in all but the 0·5 mg group and greater than 1·5 mg dulaglutide in the 8 mg slow escalation group (p=0·0019) and 12 mg escalation group (p=0·0002).
Summary · context
The primary endpoint was change in HbA_1c from baseline to 24 weeks, and secondary endpoints included change in HbA_1c and bodyweight at 36 weeks.
Report a problemFND-3738528031
13HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the HbA1c findings with retatrutide at 36 weeks were consistent with those at 24 weeks.
In plain wordsIn adults with type 2 diabetes, the HbA1c results with retatrutide at 36 weeks matched those at 24 weeks.
Peptide
Retatrutide
Outcome
DecreaseHbA1c change at 36 weeks
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 to 12 mg once weekly · injection · 36 weeksAs given in this study (human).
Source sentences
Summary
Findings were consistent at 36 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528011
14HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, body weight fell by 3.19% at 36 weeks with retatrutide 0.5 mg, similar to the 3.00% fall with placebo.
In plain wordsIn adults with type 2 diabetes, body weight fell at 36 weeks with retatrutide 0.5 mg, and fell by about the same with placebo.
Peptide
Retatrutide
Outcome
DecreaseBody weight change at 36 weeks, 0.5 mg
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
0.5 mg once weekly · injection · 36 weeksAs given in this study (human).
Measurements
Body weight decrease
3.19%
0.5 mg, week 36
Source sentences
Summary
3·19% (SE 0·61) for the 0·5 mg group
3 context sentences(design, population, supporting numbers)
Summary · context
Bodyweight decreased dose dependently with retatrutide at 36 weeks by
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528012
15HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, body weight fell by 7.92% at 36 weeks with retatrutide 4 mg (escalation).
In plain wordsIn adults with type 2 diabetes, body weight fell at 36 weeks with retatrutide 4 mg.
Peptide
Retatrutide
Outcome
DecreaseBody weight change at 36 weeks, 4 mg escalation
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
4 mg once weekly (escalation group) · injection · 36 weeksAs given in this study (human).
Measurements
Body weight decrease
7.92%
4 mg escalation, week 36
Source sentences
Summary
7·92% (1·28) for the 4 mg escalation group
3 context sentences(design, population, supporting numbers)
Summary · context
Bodyweight decreased dose dependently with retatrutide at 36 weeks by
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528013
16HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, body weight fell by 10.37% at 36 weeks with retatrutide 4 mg.
In plain wordsIn adults with type 2 diabetes, body weight fell at 36 weeks with retatrutide 4 mg.
Peptide
Retatrutide
Outcome
DecreaseBody weight change at 36 weeks, 4 mg
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
4 mg once weekly · injection · 36 weeksAs given in this study (human).
Measurements
Body weight decrease
10.37%
4 mg, week 36
Source sentences
Summary
10·37% (1·56) for the 4 mg group
3 context sentences(design, population, supporting numbers)
Summary · context
Bodyweight decreased dose dependently with retatrutide at 36 weeks by
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528014
17HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, body weight fell by 16.81% at 36 weeks with retatrutide 8 mg (slow escalation).
In plain wordsIn adults with type 2 diabetes, body weight fell at 36 weeks with retatrutide 8 mg.
Peptide
Retatrutide
Outcome
DecreaseBody weight change at 36 weeks, 8 mg slow escalation
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
8 mg once weekly (slow escalation group) · injection · 36 weeksAs given in this study (human).
Measurements
Body weight decrease
16.81%
8 mg slow escalation, week 36
Source sentences
Summary
16·81% (1·59) for the 8 mg slow escalation group
3 context sentences(design, population, supporting numbers)
Summary · context
Bodyweight decreased dose dependently with retatrutide at 36 weeks by
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528015
18HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, body weight fell by 16.34% at 36 weeks with retatrutide 8 mg (fast escalation).
In plain wordsIn adults with type 2 diabetes, body weight fell at 36 weeks with retatrutide 8 mg.
Peptide
Retatrutide
Outcome
DecreaseBody weight change at 36 weeks, 8 mg fast escalation
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
8 mg once weekly (fast escalation group) · injection · 36 weeksAs given in this study (human).
Measurements
Body weight decrease
16.34%
8 mg fast escalation, week 36
Source sentences
Summary
16·34% (1·65) for the 8 mg fast escalation group
3 context sentences(design, population, supporting numbers)
Summary · context
Bodyweight decreased dose dependently with retatrutide at 36 weeks by
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528016
19HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, body weight fell by 16.94% at 36 weeks with retatrutide 12 mg (escalation).
In plain wordsIn adults with type 2 diabetes, body weight fell at 36 weeks with retatrutide 12 mg.
Peptide
Retatrutide
Outcome
DecreaseBody weight change at 36 weeks, 12 mg escalation
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
12 mg once weekly (escalation group) · injection · 36 weeksAs given in this study (human).
Measurements
Body weight decrease
16.94%
12 mg escalation, week 36
Source sentences
Summary
16·94% (1·30) for the 12 mg escalation group
3 context sentences(design, population, supporting numbers)
Summary · context
Bodyweight decreased dose dependently with retatrutide at 36 weeks by
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528017
20HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, weight decreases with retatrutide 4 mg and higher were significantly greater than with placebo.
In plain wordsIn adults with type 2 diabetes, retatrutide at 4 mg and higher cut weight more than placebo.
Peptide
Retatrutide
Outcome
DecreaseBody weight vs placebo at 36 weeks, 4 mg and higher
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
4 mg and higher · injection · 36 weeksAs given in this study (human).
Source sentences
Summary
For retatrutide doses of 4 mg and greater, decreases in weight were significantly greater than with placebo (p=0·0017 for the 4 mg escalation group and p<0·0001 for others) and 1·5 mg dulaglutide (all p<0·0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528018
21HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, weight decreases with retatrutide 4 mg and higher were significantly greater than with dulaglutide 1.5 mg (all p<0.0001).
In plain wordsIn adults with type 2 diabetes, retatrutide at 4 mg and higher cut weight more than dulaglutide 1.5 mg.
Peptide
Retatrutide
Outcome
DecreaseBody weight vs dulaglutide at 36 weeks, 4 mg and higher
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
4 mg and higher · injection · 36 weeksAs given in this study (human).
Source sentences
Summary
For retatrutide doses of 4 mg and greater, decreases in weight were significantly greater than with placebo (p=0·0017 for the 4 mg escalation group and p<0·0001 for others) and 1·5 mg dulaglutide (all p<0·0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528019
22HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, there were no reports of severe hypoglycaemia during the study.
In plain wordsIn adults with type 2 diabetes given retatrutide, no severe low blood sugar was reported during the study.
Peptide
Retatrutide
Outcome
No significant changeSevere hypoglycaemia
Study
n = 281
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.5 to 12 mg once weekly · injectionAs given in this study (human).
Source sentences
Summary
There were no reports of severe hypoglycaemia and no deaths during the study.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528021
23HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, there were no deaths during the study.
In plain wordsIn adults with type 2 diabetes given retatrutide, no deaths were reported during the study.
Peptide
Retatrutide
Outcome
No significant changeDeaths
Study
n = 281
Outcome group
Mortality · Whole body
Studied dose
0.5 to 12 mg once weekly · injectionAs given in this study (human).
Source sentences
Summary
no deaths during the study.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528022
24HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, mild-to-moderate gastrointestinal adverse events occurred in 35% of retatrutide recipients, versus 13% with placebo and 35% with dulaglutide.
In plain wordsIn adults with type 2 diabetes, mild-to-moderate stomach and gut side effects occurred in 35% on retatrutide, versus 13% on placebo and 35% on dulaglutide.
Peptide
Retatrutide
Outcome
IncreaseGastrointestinal adverse events
Study
n = 190
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.5 to 12 mg once weekly · injectionAs given in this study (human).
Measurements
GI adverse event incidence
35%
all retatrutide groups
GI adverse event incidence
13%
retatrutide 0.5 mg
GI adverse event incidence
50%
retatrutide 8 mg fast escalation
Source sentences
Summary
Mild-to-moderate gastrointestinal adverse events, including nausea, diarrhoea, vomiting, and constipation, were reported in 67 (35%) of 190 participants in the retatrutide groups (from six [13%] of 47 in the 0·5 mg group to 12 [50%] of 24 in the 8 mg fast escalation group)
3 context sentences(design, population, supporting numbers)
Summary · context
six (13%) of 45 participants in the placebo group, and 16 (35%) of 46 participants in the 1·5 mg dulaglutide group.
Summary · context
In this randomised, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, participants were recruited from 42 research and health-care centres in the USA.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528020
25HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, mild-to-moderate gastrointestinal adverse events occurred in 35% of dulaglutide recipients.
In plain wordsIn adults with diabetes, 35% of dulaglutide recipients reported mild-to-moderate gastrointestinal adverse events.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableGastrointestinal adverse events
Study
n = 46
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1·5 mg · injectionAs given in this study (human).
Measurements
Gastrointestinal adverse events
35%
Dulaglutide
Participants with gastrointestinal events
16 participants
Dulaglutide
Source sentences
Summary
Mild-to-moderate gastrointestinal adverse events, including nausea, diarrhoea, vomiting, and constipation, were reported in 67 (35%) of 190 participants in the retatrutide groups (from six [13%] of 47 in the 0·5 mg group to 12 [50%] of 24 in the 8 mg fast escalation group), six (13%) of 45 participa…
1 context sentence(design, population, supporting numbers)
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528028
26HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, no severe hypoglycaemia occurred during the study, including in the dulaglutide arm.
In plain wordsIn adults with diabetes, no severe low blood sugar occurred during the study, including with dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableSevere hypoglycaemia
Study
n = 46
Outcome group
Adverse events · Metabolic and weight
Studied dose
1·5 mg · injectionAs given in this study (human).
Source sentences
Summary
There were no reports of severe hypoglycaemia and no deaths during the study.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528029
27HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, no deaths occurred during the study, including in the dulaglutide arm.
In plain wordsIn adults with diabetes, no deaths occurred during the study, including with dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDeaths
Study
n = 46
Outcome group
Mortality · Whole body
Studied dose
1·5 mg · injectionAs given in this study (human).
Source sentences
Summary
There were no reports of severe hypoglycaemia and no deaths during the study.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
Report a problemFND-3738528030
28HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, dulaglutide reduced HbA1c less than retatrutide in the 8 mg slow escalation group.
In plain wordsIn adults with diabetes, dulaglutide reduced blood sugar less than retatrutide 8 mg with slow escalation.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c reduction versus retatrutide slow escalation
Study
n: not reported in source
Comparator
Retatrutide 8 mg slow escalation
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1·5 mg · injection · 24 weeksAs given in this study (human).
Measurements
HbA1c change from baseline (least-squares mean)
−1.41%
Dulaglutide 1.5 mg, 24 weeks
HbA1c change from baseline (least-squares mean)
−1.99%
Retatrutide 8 mg slow escalation, 24 weeks
Source sentences
Summary
HbA_1c reductions with retatrutide were significantly greater (p<0·0001) than placebo in all but the 0·5 mg group and greater than 1·5 mg dulaglutide in the 8 mg slow escalation group (p=0·0019) and 12 mg escalation group (p=0·0002).
2 context sentences(design, population, supporting numbers)
Summary · context
-1·99% (0·15; -21·78 mmol/mol [1·60]) for the 8 mg slow escalation group
Summary · context
-1·41% (0·12; -15·40 mmol/mol [1·29]) for the 1·5 mg dulaglutide group
Report a problemFND-3738528024
29HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, dulaglutide reduced HbA1c less than retatrutide in the 12 mg escalation group.
In plain wordsIn adults with diabetes, dulaglutide reduced blood sugar less than retatrutide 12 mg with escalation.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c reduction versus retatrutide escalation
Study
n: not reported in source
Comparator
Retatrutide 12 mg escalation
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1·5 mg · injection · 24 weeksAs given in this study (human).
Measurements
HbA1c change from baseline (least-squares mean)
−1.41%
Dulaglutide 1.5 mg, 24 weeks
HbA1c change from baseline (least-squares mean)
−2.02%
Retatrutide 12 mg escalation, 24 weeks
Source sentences
Summary
HbA_1c reductions with retatrutide were significantly greater (p<0·0001) than placebo in all but the 0·5 mg group and greater than 1·5 mg dulaglutide in the 8 mg slow escalation group (p=0·0019) and 12 mg escalation group (p=0·0002).
2 context sentences(design, population, supporting numbers)
Summary · context
-2·02% (0·11; -22·07 mmol/mol [1·21]) for the 12 mg escalation group
Summary · context
-1·41% (0·12; -15·40 mmol/mol [1·29]) for the 1·5 mg dulaglutide group
Report a problemFND-3738528025
30HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, dulaglutide reduced weight less than retatrutide doses of 4 mg and greater.
In plain wordsIn adults with diabetes, dulaglutide reduced weight less than retatrutide doses of 4 mg and greater.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseBodyweight reduction versus retatrutide
Study
n: not reported in source
Comparator
Retatrutide doses of 4 mg and greater
Outcome group
Body weight · Metabolic and weight
Studied dose
1·5 mg · injection · 36 weeksAs given in this study (human).
Measurements
Bodyweight decrease
2.02%
Dulaglutide 1.5 mg, 36 weeks
Bodyweight decrease
7.92%
Retatrutide 4 mg escalation, 36 weeks
Bodyweight decrease
10.37%
Retatrutide 4 mg, 36 weeks
Bodyweight decrease
16.81%
Retatrutide 8 mg slow escalation, 36 weeks
Bodyweight decrease
16.34%
Retatrutide 8 mg fast escalation, 36 weeks
Bodyweight decrease
16.94%
Retatrutide 12 mg escalation, 36 weeks
Source sentences
Summary
For retatrutide doses of 4 mg and greater, decreases in weight were significantly greater than with placebo (p=0·0017 for the 4 mg escalation group and p<0·0001 for others) and 1·5 mg dulaglutide (all p<0·0001).
2 context sentences(design, population, supporting numbers)
Summary · context
7·92% (1·28) for the 4 mg escalation group, 10·37% (1·56) for the 4 mg group, 16·81% (1·59) for the 8 mg slow escalation group, 16·34% (1·65) for the 8 mg fast escalation group, and 16·94% (1·30) for the 12 mg escalation group
Summary · context
versus 3·00% (0·86) with placebo and 2·02% (0·72) with 1·5 mg dulaglutide.
Report a problemFND-3738528027

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

31HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, bodyweight fell by 2·02% with dulaglutide and by 3·00% with placebo at 36 weeks, a decrease seen in both groups.
In plain wordsIn adults with diabetes, weight fell by 2·02% with dulaglutide and 3·00% with placebo at 36 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBodyweight change at 36 weeks
Study
n: not reported in source
Comparator
Baseline
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Measurements
Bodyweight decrease
2.02%
Dulaglutide 1.5 mg, bodyweight decrease at 36 weeks
Bodyweight decrease
3%
Placebo, bodyweight decrease at 36 weeks
Source sentences
Summary
versus 3·00% (0·86) with placebo and 2·02% (0·72) with 1·5 mg dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was change in HbA_1c from baseline to 24 weeks, and secondary endpoints included change in HbA_1c and bodyweight at 36 weeks.
Summary · context
Adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA_1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m² were eligible for enrolment.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3738528026

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT04867785

A Study of LY3437943 in Participants With Type 2 Diabetes

Eli Lilly and Companyn = 28113 May 2021 to 27 Oct 2022

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 3 Jul 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.